Janssen Search
Search results
Discoveries in Immunology Disease Treatment
Discovery: Embracing New Ideas to Build a Promising Pipeline for the Future Submerged monolayer culture of colonic epithelial cells More than two decades ago, our scientists pioneered the use of antibodies to tumor necrosis factor (TNF)-alpha to treat ...
Eric Schaeffer, Ph.D.
ERIC SCHAEFFER, PH.D. SENIOR DIRECTOR NEUROSCIENCE INNOVATION BOSTON INNOVATION CENTER Eric Schaeffer, Ph.D. received his degree from the Albert Einstein College of Medicine in New York City, and went on to do post-doctoral fellowships at the ...
Christopher Stevenson Ph.D.
As the Chronic Obstructive Pulmonary Disease (COPD) Venture Leader for the Disease Interception Accelerator (DIA), Christopher leads efforts focused on pinpointing individuals who are at risk and in the earliest stages of COPD using radiology and ...
Johnson & Johnson Completes Acquisition of Ambrx
Mar 07, 2024 United Stats Acquisition strengthens Johnson & Johnson’s commitment to innovation in prostate cancer and deepens pipeline of next-generation antibody drug conjugates and targeted oncologic therapeutics NEW BRUNSWICK, NJ (March 7, 2024) ...
Bacterial Infections
Bacterial Infections We refuse to stand still while bacterial infections continue to evade our control. Structure of E. coli We are working urgently to help protect society from the consequences of Extraintestinal Pathogenic E. coli (ExPEC) and ...
CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations
Jun 28, 2024 Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s most common cancers 1 The CHMP’s recommendation is based on results from Cohort 1 of ...
Janssen Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of BALVERSA® (erdafitinib) for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Carcinoma and Selected Fibroblast Grow
Aug 28, 2023 United States Submission Based on Confirmatory Data from Cohort 1 of the Phase 3 THOR Study, Which Showed a 36 Percent Reduction in the Risk of Death in Patients Treated with BALVERSA ® Versus Chemotherapy RARITAN, N.J., August 28, 2023 – ...
U.S. FDA Approves AKEEGA™ (Niraparib and Abiraterone Acetate), the First-And-Only Dual Action Tablet for the Treatment of Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
Aug 11, 2023 United States Approval is based on the Phase 3 MAGNITUDE study, a prospectively designed precision medicine study including the largest population of BRCA-positive patients in combination trials to date with metastatic castration-resistant ...
Candice Long
CANDICE LONG WORLDWIDE VICE PRESIDENT IMMUNOLOGY Candice Long is the Worldwide Vice President for the Immunology Therapeutic Area with Janssen Pharmaceutical Companies of Johnson & Johnson. Together with the Immunology Research & Development ...
Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
Feb 16, 2023 United States Results from the Phase 3 MAGNITUDE study second interim analysis to be featured in an oral presentation at ASCO GU SAN FRANCISCO, Feb. 16, 2023 -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced ...